A brain plaque inhibitor developed by Merck is now being tested in larger studies for efficacy against the still unstoppable neurodegenerative disease.  {read more here}

Amyloid brain scans can change diagnosis and treatment choice in patients with cognitive impairment, but debate about clinical utility is far from over, researchers reported. {read more here}

Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of “The Journal of Nuclear Medicine.” {read more here}

A new analysis of more than 900 participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), all of whom had amnestic mild cognitive impairment (aMCI) or AD dementia, and almost 400 healthy controls showed that women in all three groups had better verbal memory scores at baseline than men. {read more here}